# ImpriMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imprimed

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.imprimedicine.com
- Total disclosed funding: $37M
- Latest round: Series A (Sep 18, 2026)
- Investors on record: 23

## About

Based in California, US, ImpriMed, Inc. is a developer of customized drug response testing solutions for pet cancer patients. Founded in 2017 by Sungwon Lim (CEO) and Jamin Koo (CTO), the company collects test results and builds a database of patient cell responses to FDA-approved drugs to support the development of personalized therapeutic regimens. In September 2026, ImpriMed, Inc. raised USD 10 million in Series A funding led by LB Investment, with participation from Naver D2 Startup Factory, Samsung Securities, Alois Ventures, BonAngels Venture Partners and Han River Partners.

ImpriMed, Inc. develops artificial intelligence-powered precision medicine solutions that help identify the most effective cancer treatments for individual patients. Its offerings include drug response prediction services, live-cell drug sensitivity testing, and research services that support oncology drug development for pharmaceutical and biotechnology companies.

The company generates revenue through veterinary oncology diagnostic and drug-response testing services, human precision medicine analytics, and contract research (CRO) services provided to pharmaceutical companies.

The company plans to use the September 2026 funding to advance clinical regulatory approvals and support commercialization efforts in the US.

## Funding rounds

- Series A, Sep 18, 2026, $10M — LB Investment, BonAngels Venture Partners, Samsung Securities, Naver D2 Startup Factory, Alois Ventures, Han River Partners
- Series A, Dec 19, 2023, $23M — Mayo Clinic, Korea Development Bank, SK Telecom Ventures, Murex Investments, SBVA, SAMYANG CHEMICAL, Han River Partners, Ignite Innovation, Byucksan Corporation
- Series A, Aug 1, 2018, $3.7M — BonAngels Venture Partners, Draper, Ironfire Ventures, Stanford-StartX Fund, SEMA Translink Investment, Blue Bear Ventures, Draper Dragon, Nextrans, Murex Partners, Sazze Partners

## Investors

- BonAngels Venture Partners (https://capitalatlas.ai/funds/bonangels-venture-partners) — Series A
- Draper (https://capitalatlas.ai/funds/draper) — Series A
- Ironfire Ventures (https://capitalatlas.ai/funds/ironfire-ventures) — Series A
- Stanford-StartX Fund — Series A
- SEMA Translink Investment — Series A
- Blue Bear Ventures (https://capitalatlas.ai/funds/blue-bear-ventures) — Series A
- Draper Dragon (https://capitalatlas.ai/funds/draper-dragon) — Series A
- Nextrans (https://capitalatlas.ai/funds/nextrans) — Series A
- Murex Partners (https://capitalatlas.ai/funds/murex-partners) — Series A
- Sazze Partners (https://capitalatlas.ai/funds/sazze-partners) — Series A
- Mayo Clinic — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series A
- SK Telecom Ventures — Series A
- Murex Investments (https://capitalatlas.ai/funds/murex-investments) — Series A
- SBVA (https://capitalatlas.ai/funds/sbva) — Series A
- SAMYANG CHEMICAL — Series A
- Han River Partners (https://capitalatlas.ai/funds/han-river-partners) — Series A
- Ignite Innovation (https://capitalatlas.ai/funds/ignite-innovation) — Series A
- Byucksan Corporation — Series A
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series A
- Samsung Securities — Series A
- Naver D2 Startup Factory (https://capitalatlas.ai/funds/naver-d2-startup-factory) — Series A
- Alois Ventures — Series A